MANNKIND CORP Long-term Purchase Commitment, Amount
MANNKIND CORP (MNKD) reported Long-term Purchase Commitment, Amount of EUR 90.30 million for the 6-month period ending 2019-06-30, per its 10-Q filed 2019-08-07.
Discontinued › Notes › Commitment and Contingencies
us-gaap:LongTermPurchaseCommitmentAmount · last filed 2019-08-07
- MANNKIND CORP long-term purchase commitment, amount for the quarter ending 2019-06-30 was 0.00 EUR.
- MANNKIND CORP long-term purchase commitment, amount for the quarter ending 2019-03-31 was 90.30M EUR, a 0.00% change year-over-year.
- MANNKIND CORP long-term purchase commitment, amount for the quarter ending 2018-12-31 was 4.50M EUR.
- MANNKIND CORP long-term purchase commitment, amount for the quarter ending 2018-09-30 was 0.00 EUR.
- MANNKIND CORP long-term purchase commitment, amount for fiscal 2018 was 90.30M EUR, a 0.00% change from fiscal 2017.
- MANNKIND CORP long-term purchase commitment, amount for fiscal 2017 was 90.30M EUR, a 2.90% decline from fiscal 2016.
- MANNKIND CORP long-term purchase commitment, amount for fiscal 2016 was 93.00M EUR.
| Period end | Long-term Purchase Commitment, Amount | Long-term Purchase Commitment, Amount 3 month | Long-term Purchase Commitment, Amount 6 month | Long-term Purchase Commitment, Amount 9 month | Long-term Purchase Commitment, Amount 12 month |
|---|---|---|---|---|---|
| 2019-06-30 | 0.00 EUR derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-07 | 90.30M EUR 10-Q · filed 2019-08-07 | 94.80M EUR derived: sum of 3 quarters · filed 2019-08-07 | 94.80M EUR derived: sum of 4 quarters · filed 2019-08-07 | |
| 2019-03-31 | 90.30M EUR 10-Q · filed 2019-05-07 | 94.80M EUR derived: sum of 2 quarters · filed 2019-05-07 | 94.80M EUR derived: sum of 3 quarters · filed 2019-05-07 | 90.30M EUR derived: sum of 4 quarters · filed 2019-05-07 | |
| 2018-12-31 | 4.50M EUR derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-26 | 4.50M EUR derived: sum of 2 quarters · filed 2019-02-26 | 0.00 EUR derived: sum of 3 quarters · filed 2019-02-26 | 90.30M EUR 10-K · filed 2019-02-26 | |
| 2018-09-30 | 0.00 EUR derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-01 | -4.50M EUR derived: sum of 2 quarters · filed 2018-11-01 | 85.80M EUR 10-Q · filed 2018-11-01 | 83.10M EUR derived: sum of 4 quarters · filed 2018-11-01 | |
| 2018-06-30 | -4.50M EUR derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-02 | 85.80M EUR 10-Q · filed 2018-08-02 | 83.10M EUR derived: sum of 3 quarters · filed 2018-08-02 | 83.10M EUR derived: sum of 4 quarters · filed 2018-08-02 | |
| 2018-03-31 | 90.30M EUR 10-Q · filed 2018-05-09 | 87.60M EUR derived: sum of 2 quarters · filed 2018-05-09 | 87.60M EUR derived: sum of 3 quarters · filed 2018-05-09 | 87.60M EUR derived: sum of 4 quarters · filed 2018-05-09 | |
| 2017-12-31 | -2.70M EUR derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-27 | -2.70M EUR derived: sum of 2 quarters · filed 2018-02-27 | -2.70M EUR derived: sum of 3 quarters · filed 2018-02-27 | 90.30M EUR 10-K · filed 2018-02-27 | |
| 2017-09-30 | 0.00 EUR derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-07 | 0.00 EUR derived: sum of 2 quarters · filed 2017-11-07 | 93.00M EUR 10-Q · filed 2017-11-07 | ||
| 2017-06-30 | 0.00 EUR derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-07 | 93.00M EUR 10-Q · filed 2017-08-07 | |||
| 2017-03-31 | 93.00M EUR 10-Q · filed 2017-05-10 | ||||
| 2016-12-31 | 93.00M EUR 10-K · filed 2017-03-16 | ||||
| 2014-07-31 | 120.10M EUR 10-Q · filed 2016-11-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| Seaport Therapeutics, Inc. (SPTX) | United States | $1.131B | |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 |